Insider Selling: Assembly Biosciences, Inc. (NASDAQ:ASMB) CEO Sells 1,569 Shares of Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) CEO Jason A. Okazaki sold 1,569 shares of the company’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $12.71, for a total transaction of $19,941.99. Following the transaction, the chief executive officer now owns 16,423 shares of the company’s stock, valued at $208,736.33. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Assembly Biosciences Trading Up 6.4 %

ASMB opened at $13.27 on Thursday. The firm’s fifty day moving average price is $13.17 and its two-hundred day moving average price is $11.15. Assembly Biosciences, Inc. has a fifty-two week low of $7.69 and a fifty-two week high of $20.04.

Analyst Upgrades and Downgrades

ASMB has been the subject of several research reports. StockNews.com upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, April 5th. HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a report on Monday, April 1st.

Institutional Trading of Assembly Biosciences

An institutional investor recently bought a new position in Assembly Biosciences stock. Marquette Asset Management LLC bought a new position in Assembly Biosciences, Inc. (NASDAQ:ASMB) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned approximately 0.08% of Assembly Biosciences at the end of the most recent quarter. 19.92% of the stock is owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.